# Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People

> **NCT06675851** · PHASE4 · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 120 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
- **DRUG:** Cipralex (escitalopram)

## Key facts

- **NCT ID:** NCT06675851
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675851, "Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06675851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*